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Abstract 
Background: This study was carried out at district level to describe the cost structure and measure the effectiveness 
of delivering supplementary immunization activity (SIA) and routine immunization (RI) for measles in Benin, a country 
heavily affected by this disease.
Methods: This cost-effectiveness study was cross sectional and considered 1-year time horizon. RI consists to vac-
cinate an annual cohort of children aged 0–1 year old and SIA consists to provide a second dose of measles vaccine 
to children aged 0–5 years old in order to reach both those who did not seroconvert and who were not vaccinated 
through RI. Ingredients approach to costing was used. Effectiveness indicators included measles vaccine doses used, 
vaccinated children, measles cases averted and disability adjusted life years averted. Data were collected from all the 
18 health care centers of the health district of Natitingou for the year 2011. In the analysis, the coverage was 89 % for 
RI and 104 % for SIA.
Results: SIA total cost was higher than RI total cost (15,796,560 FCFA versus 9,851,938 FCFA). Personnel and vaccines 
were the most important cost components for the two strategies. Fuel for cold chain took a non-negligible part of RI 
total cost (4.03 %) because 83 % of refrigerators were working with kerosene. Cost structures were disproportionate 
as social mobilization and trainings were not financed during RI contrarily to SIA. In comparison with no intervention, 
the two strategies combined permitted to avoid 12,671 measles cases or 19,023 DALYs. The benefit of SIA was 5601 
measles cases averted and 6955 additional DALYs averted. Cost per vaccinated child for SIA (442 FCFA) was lower than 
for RI (1242 FCFA), in line with previous data from the literature. Cost per DALY averted was 2271 FCFA (4.73 USD) for 
SIA and 769 FCFA (1.60 USD) for RI. Analysis showed that low vaccine efficacy decreased the cost-effectiveness ratios 
for the two strategies. SIA was more cost-effective when the proportion of previously unvaccinated children was 
higher. For the two strategies, costs per DALY were more likely to vary with measles case fatality ratio.
Conclusions: SIA is costlier than RI. Both SIA and RI for measles are cost-effective interventions to improve health in 
Benin compared to no vaccination. Policy makers could make RI more efficient if sufficient funds were allocated to 
communications activities and to staff motivation (trainings, salaries).
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Background
Measles is one of the most serious infectious human dis-
eases as it can cause severe illness, lifelong complications 
and death. WHO estimated 45 million measles cases 
and 1.1 million measles related deaths occurring each 
year in developing countries [1]. Benin is one of the 47 
measles high burden countries in the world [2]. To meet 
measles mortality and morbidity reduction goals, WHO 
recommended four strategies: (1) strengthening routine 
immunization to achieve and sustain high coverage, (2) 
providing a second opportunity for measles immuni-
zation, (3) conducting epidemiologic surveillance with 
high laboratory confirmation of cases and outbreaks 
and (4) insuring that improved case management is 
implemented.
Benin is a small country of West Africa (112,622 Km2; 
7,862,944 inhabitants) [3]. It is a low income coun-
try divided in 33 health districts. The health district of 
Natitingou is located in the north east region of Benin. 
It is a mountainous region. It covers an area of 3760 Km2 
with 222,785 inhabitants estimated in 2011 (projection 
from 2002 national census); most of them are farmers [4]. 
There are 18 health facilities that provide immunization 
services.
The first dose of measles containing vaccine (MCV) is 
given in Benin to children at 9 months through Routine 
Immunization program (RI). The second opportunity 
for measles immunization is provided through Supple-
mentary Immunization Activities (SIAs). These SIAs 
are follow-up campaigns conducted every 3  years since 
2001 and targeting children aged 0–59 months. The sec-
ond opportunity for measles vaccination aims at reach-
ing children who were not vaccinated through RI and to 
protect children who did not seroconvert with the first 
dose. By doing so, the population could reach the 95  % 
population immunity threshold (herd immunity) neces-
sary to stop measles virus circulation. By organizing SIAs 
campaigns, Benin saw a dramatic fall of measles reported 
cases with 334 measles cases reported in the first semes-
ter of the year 2011 while 5531 cases where annually 
reported on average during the decade 1991–2000 [5]. RI 
consists in providing all vaccinations listed in a country 
immunization program schedule. Services are delivered 
on an ongoing basis from permanent locations through-
out the year. RI usually targets children under 1 year of 
age. In Benin, the following vaccines are administrated 
through RI to children under 1  year and to pregnant 
women: BCG, Pentavalent (DTP-Hep-Hib), OPV, MCV, 
PCV13, YFV and TT. SIAs are provided from multiple 
permanent and temporary locations. These campaigns 
usually have a short duration (1  week) and target chil-
dren under 5 or 15. RI target population of children aged 
0–12  months was estimated to 8911 children and SIA 
target population was estimated to 34,131 children aged 
0–59  months, both for the year 2011. During this year, 
7933 children under 1 year old were reached through RI 
corresponding to a coverage of 89  %. SIA permitted to 
vaccinate 35,564 children aged 0–59 months correspond-
ing to a coverage of 104 %. A coverage rate of >100 % is 
commonly observed during SIAs in Benin, usually related 
to an inaccurate estimation of the target population 
because the number of eligible children came from not 
up-to-date national census data.
In a context of global economic crisis and resources 
scarcity, efficiency of measles immunization strategies 
needs to be taken into account in African health dis-
tricts heavily affected by this disease. The operational 
level needs to know the economic value of their activi-
ties as this could help them to get more results at a lesser 
or equivalent costs. Ignorance of measles immunization 
costs, neglect of these costs, ignorance of the relative 
weight of cost components and lack of knowledge of the 
financial needs cause difficulties in planning, resources 
mobilization and resources allocation. Nothing is known 
about the efficiency of SIA and RI for measles in Benin. 
To fill this gap, this work was initiated by the health 
district of Natitingou using primary data from routine 
immunization and measles mass campaign for the year 
2011.
The first objective of this paper was to describe cost 
structure of measles immunization strategies (RI and 
SIA) in a rural health district. Secondary, this study 
aimed at measuring the benefits of these strategies on 
population health. Finally, we assessed the efficiency of 
each strategy and we compared the cost-effectiveness 
ratios with a ‘no vaccination’ strategy. Effectiveness indi-
cators took into account not only the immediate results 
of immunization (vaccine doses used, vaccinated chil-
dren) but also the impact on final health outcomes (mea-
sles cases averted, disability adjusted life years averted). 
This work will help immunization services providers at 
health facility level to streamline measles immunization 
practices for a greater efficiency. The results could also 
provide guidance to policy makers in Benin for resources 
allocation.
Methods
This study was a cross-sectional cost-effectiveness anal-
ysis of delivering measles RI and SIA for the year 2011 
in the health district of Natitingou. Data were collected 
retrospectively and the analysis has only considered one-
year time horizon. All the 18 health care centers deliv-
ering immunization services were included. Data were 
analyzed by Microsoft Excel software.
RI is a component of the minimum package of activi-
ties provided in health facilities in Benin. RI services were 
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provided in the 18 health facilities through two strategies: 
fixed and outreach strategy. Fixed strategy was planned 
for children living within less than 5 km from the health 
center and outreach strategy was planned for children 
living beyond 5  km from the facility. Health workers 
planned two fixed strategies sessions and 1 outreach 
strategy session per week. All health care centers had 
the same configuration: one dispensary and one mater-
nity ward. Staff consisted of 4 persons: a nurse, a midwife 
and two caregivers. All staffs were equitably involved in 
immunization activities. Vaccines were supplied monthly 
by the district team from the regional storehouse to three 
secondary storehouses of the district. Health workers 
were responsible for transporting vaccines from the dis-
trict storehouses to their respective health facilities by 
motorcycle. Health facilities were equipped with cold 
chain materials (refrigerators, cold boxes, vaccines carri-
ers) and motorcycles. Data on the number of vaccinated 
children were collected on tally sheets at each immuni-
zation session. A synthesis was made at the end of the 
month by the head of the health center before transmis-
sion to district team.
The Ministry of Health planned SIA for measles to vac-
cinate children unreached through RI and to enhance 
immunity of children remained susceptible despite the 
first dose of vaccine received. A micro planning was done 
at district level taking into account human, logistical and 
financial needs. The strategy adopted was vaccination at 
fixed locations to which parents should bring children. 
A total of 29 vaccination posts were set up. Vaccination 
team at a station consisted of 3 persons (2 health work-
ers and 1 volunteer) and should vaccinate at least 250 
children per day. Supervision of vaccination teams was 
ensured by 6 supervisors who should supervise each 6 
teams per day. Supervisors and vaccinators had been 
trained during a 1-day training session. Communication 
activities were strengthened with involvement of town 
criers.
Measuring costs
Costs taken into account included recurrent and capi-
tal costs. Both economic and financial costs were 
considered. Some costs were specific to measles immu-
nization and others were shared with others activities. 
Data for SIA specific operational costs came from the 
campaign financial reports and micro planning tools. 
Shared costs for measles RI activities were supposed 
to represent 9  % of RI delivery total costs; as measles 
vaccine was one of the 11 antigens administrated in 
Benin RI schedule. RI recurrent costs were analyzed 
using ingredients approach to costing. Data on vac-
cines used, consumables and management tools used 
were empirically obtained at health facilities level from 
vaccine usage reports, tally sheets, vaccine manage-
ment databases. Costs for personnel, transport, super-
vision, trainings, fuel for cold chain, electricity and 
maintenance were obtained from interviews, question-
naires, direct surface measurement of buildings and 
exploitation of documents (administrative and financial 
reports, log books), both at health facilities and district 
administration level. Costs were expressed in local cur-
rency (FCFA) and in USD, using a fixed exchange rate 
of 480 FCFA for 1  USD (2011 average exchange rate 
from http://oanda.com).
Recurrent costs components included: vaccines, con-
sumables, management tools, personnel, transport, 
maintenance, supervision, trainings, social mobilization, 
fuel for cold chain materials functioning and electricity 
bills:
  • Vaccines costs were calculated by multiplying the 
cost per dose of MCV by the number of doses used. 
MCV dose unit price was 0.24  USD, derived from 
National EPI vaccine’s purchase orders.
  • Consumables included syringes (auto disable and 
dilution), safety boxes and cotton. Cost per unit of 
syringes and safety boxes were derived from WHO’s 
Pre Qualify Standard (PQS) devices catalogue [6]. 
The amount of medical accessories used was esti-
mated on the basis of immunization management 
report. The same method was used to estimate the 
cost of management tools (data collection spread-
sheets, registers).
  • Personnel costs were defined by wages and allow-
ances paid to the staff involved in immunization 
activities. They were calculated by exploitation of 
staff payment vouchers and other documents con-
sidering the estimated proportion of time spent for 
immunization activities. Staff devoted 2  days per 
week to fixed strategy sessions and 1  day per week 
to outreach strategy sessions. A fixed strategy ses-
sion took 4 h corresponding to half of a daily work-
ing time. An outreach strategy session took all the 
daily working time, as vaccination teams had to travel 
more than 5 km before reaching the village were chil-
dren should be vaccinated. Roads in Natitingou were 
bad and such a distance could take one to 2 h travel-
ling by motorcycle.
  • Transport was related to expenditures for vaccine 
supply and transportation fees for outreach strate-
gies. These costs were obtained multiplying the dis-
tance covered by the average fuel consumption of the 
vehicle used and by the unit price of a liter of fuel. 
From exploitation of vehicle user’s manuals, average 
fuel consumption considered was 16  L/100  km for 
cars and 2 L/100 km for motorcycles. The unit price 
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of a liter of fuel was 625 FCFA for the year 2011 in 
the health district of Natitingou.
  • Maintenance included costs for cold chain, cars and 
motorcycles reparation and periodic maintenance. 
For cars and motorcycles, this shared cost was esti-
mated applying the proportion of kilometers devoted 
to immunization activities. Log books available in 
cars allowed to estimate kilometers covered. For 
motorcycles, distances covered were estimated from 
interviews with staff conducting immunization activ-
ities.
  • Supervision included all costs related to supportive 
supervision (per diems, fuel, reproducing manage-
ment tools). Data for this cost component came from 
exploitation of district administrative and financial 
reports.
  • Trainings corresponded to total expenditures for 
trainings organized for SIA or RI (venue hiring 
charges, training materials, per diems). No training 
was organized as part of RI. Data for SIA came from 
exploitation of the campaign financial reports avail-
able at district administration level.
  • Social mobilization was related to cost of communi-
cation activities (advocacy meetings, banners, news 
release). No expense was performed for social mobi-
lization in RI. Data for SIA came from exploitation 
of the campaign financial reports available at district 
administration level.
  • Fuel for cold chain corresponded to total cost of 
kerosene used in health facilities where cold chain 
materials were working with kerosene. There were 
18 refrigerators and 3 freezers used for immuniza-
tion activities in the health district. The 15 kerosene-
functioning refrigerators were all of the same type 
(RCW50 EK) and consumed on average 35 L of kero-
sene per month. The unit price of a liter of kerosene 
was 700 FCFA for the year 2011 in the health district 
of Natitingou.
  • Electricity was related to the shared cost of electricity 
for the 3 health care centers where cold chain mate-
rials were working with electricity. This cost compo-
nent was calculated multiplying the kilowatt-hours 
(kWh) consumption of the cold chain material used 
by the unit price of a kWh fixed by the national elec-
tricity company. Energy consumption of cold chain 
equipment were derived from WHO’s PQS devices 
catalogue [6]: 2.35  kWh per 24  h for freezers and 
0.61 kWh per 24 h for refrigerators. Electricity Com-
pany pricing was 125 FCFA per kWh.
Using linear amortization method, capital costs for 
buildings, motorcycles, cars and cold chain materials 
were estimated by dividing their respective cost by the 
useful life time. In the case of SIA, this was later divided 
by 0.019 (7 days of campaign over 365 days of the year). 
The result obtained was later multiplied first by the pro-
portion of use for immunization activities and secondary 
by the estimated proportion for measles immunization. 
Both time and space were considered for buildings (num-
ber of days used a week and proportion of surface used). 
The share of kilometer attributable to immunization 
activities was considered for cars and motorcycles. Useful 
life time considered was 50 years for buildings, 10 years 
for refrigerators, freezers, cold boxes and vaccine carri-
ers, 5 years for cars and 3 years motorcycles following the 
amortization plan of the health district.
Calculating effectiveness
Four effectiveness indicators were estimated: MCV doses 
used and vaccinated children relate to productive effi-
ciency while the number of measles cases averted and 
disability adjusted life years averted refer to allocative 
efficiency. The primary effectiveness indicator selected 
was disability adjusted life years (DALYs) averted. It is a 
widely used indicator that allows easy comparison with 
a ‘no vaccination’ strategy and with others public health 
interventions.
MCV doses used represents the amount of vac-
cines used per strategy. This was empirically obtained 
from district vaccine management tools (vaccine usage 
reports, tally sheets, vaccine management databases). 
Vaccinated children corresponds to the total of targeted 
children that received a shot, having in mind that for RI 
the target population is defined by children under 1 year 
whereas the target population for SIA extends to children 
under 5 years. Measles cases averted depend on both the 
number of vaccinated persons and vaccine efficacy. MCV 
efficacy after a single dose depends on the age of vac-
cination: 85  % of children seroconvert after receiving a 
shot when vaccination is done at the age of 9–11 months 
whereas after 1 year of age, vaccine efficacy raises to 95 % 
[7]. To facilitate comparison of final outcomes with a ‘no 
vaccination’, we estimated DALYs averted. DALY’s calcu-
lation is explained more in depth in the following section.
Disability adjusted life years
Immunization with MCV enables to increase the target 
population well-being experienced by averting deaths, 
and by averting sufferings due to measles. The concept of 
disability adjusted life years, as routinely used by WHO, 
is a useful measure of the burden of measles on popula-
tion of interest. DALYs for a specific cause are calculated 
as the sum of the years of life lost due to premature death 
(YLL) from that cause and the years of healthy life lost as 
a result of disability (YLD) for incident cases of the health 
condition as follows: DALY = YLL + YLD [8, 9].
Page 5 of 12Kaucley and Levy  Cost Eff Resour Alloc  (2015) 13:14 
YLL formula is: (N/r) ×  [1 − exp(−rLE)], where N is 
the number of deaths; LE is standard life expectancy at 
age of death and r is the discount rate. Measles deaths 
averted are estimated on the basis of the number of 
effectively immunized children after being vaccinated 
and death rate from measles related cause. The number 
of effectively immunized children depends on vaccine 
efficacy [7]. Measles case fatality ratios were age specific: 
6 % at 6–11 months and 3 % at 1–5 years [10, 11]. Stand-
ard life expectancy at birth in Benin is set as 52.5 years 
[12]. The discount rate used was 3 % in accordance with 
WHO recommendations. DALYs were calculated with-
out age weighting. Figure  1 shows the diagram used to 
estimate YLL from doses of administrated vaccine per 
strategy.
The formula for YLD calculation is: YLD  =  ∑ 
I ×  DW ×  [1 −  exp(−rL)]/r, where I is the number of 
incident cases; DW is the disability weight; L is the aver-
age duration of disability until remission or death and 
r is the discount rate. The incident cases were episodes 
of measles case and the classic complications associ-
ated with measles (diarrhea, pneumonia, otitis media, 
corneal scarring, encephalitis and subacute sclerosing 
pan encephalitis). Diarrhea is reported in 8  % of mea-
sles cases [13]. Six per cent of measles cases are com-
plicated by pneumonia and corneal scarring [13]. Otitis 
media occurs in about 7 % of cases [13]. About 1 child 
in every 1000 who get measles will develop encephalitis 
[13]. Subacute sclerosing pan encephalitis (SSE) is a rare 
degenerative central nervous system disease that occurs 
on average in 8 per 1,000,000 reported measles cases 
[13]. Duration and disease disability weights relevant for 
incident cases were extracted from the Global Burden 
of Diseases study [14]: measles episode (2 weeks, 0.152); 
diarrhea (1  week, 0.105); pneumonia (2  weeks, 0.373); 
otitis media (2 years, 0.023); corneal scarring (34.8 years, 
0.277); encephalitis (34.8  years, 0.616); SSE (36.7  years, 
0.666).
Sensitivity analysis
A one-way sensitivity analysis was used to test the 
robustness of the initial results on the cost per DALY 
averted with alternatives values of key parameters. We 
explored the variation of some cost components for RI: 
vaccines cost, staff cost, supervision cost, trainings and 
communication costs. Vaccine unit dose price varia-
tion assumed was ±50 %. We explored effects of twofold 
increase of the base-case staff cost. Increasing supervi-
sion costs by multiplying the supervision frequency from 
4 to 6 per annum was tested. Effects of adding trainings 
and communication costs in RI, the same amount as SIA 
base-case, was analyzed. To compare our results with 
studies which used only recurrent cost components, a 
sensitivity analysis was conducted to explore effects of 
excluding capital costs from the base-case analysis. As 
vaccine efficacy and measles CFR are two key param-
eters influencing the number of measles cases averted, 
we performed a sensitivity analysis for these two vari-
ables. A measles post-outbreak survey conducted in 
Democratic Republic of Congo shows that measles 
vaccine efficacy could fall to 60  % [15]. Higher mea-
sles CFRs are observed during outbreaks, among under 
5  years old children, in cases with complications and 
among children living in rural areas [16]. A review of 
25 community-based studies conducted in India shows 
that measles CFRs vary between 0.00 and 31.25 % [11]. 
As vaccination coverage affects both RI and SIA effec-
tiveness, a sensitivity analysis was performed for this 
variable. For RI, coverage variation used was 50–98  %, 
based on extreme levels achieved in the past years after 
analysis of the health district immunization databases. 
For SIA, lowest coverage used was 80 %, based on cover-
age achieved by the health district during the past SIAs. 
Because the proportion of previously unvaccinated chil-
dren during SIA (‘zero-dose’ children) is a parameter 
that allows to assess the benefit of SIA, we performed a 
sensitivity analysis on the percentage of children reached 
with the second dose. We assumed 0–50 % variation of 
‘zero dose’ children respecting the age groups propor-
tion of the base-case. Table  1 shows the base-case and 
alternatives values of parameters used in the sensitivity 
analysis. Results were presented in tornado diagrams.
Results
Costs
Overall, 25,648,498 FCFA (53,434.37  USD) were spent 
to protect children against measles in the health dis-
trict of Natitingou in 2011 (RI and SIA) (Table  2). SIA 
total cost was higher than RI total cost with respectively 
15,796,560 FCFA (32,909.50  USD) and 9,851,938 FCFA 
(20,524.87  USD). Recurrent costs took the larger cost 
share for the two strategies: 62.51 % of total cost for RI 
and 99.56 % of total cost for SIA. Personnel, and vaccines 
were the most important recurrent cost components for 
RI representing respectively 36.54 and 11.35  % of total 
cost. They were followed by fuel for cold chain material 
(4.03 %) and consumables (3.97 %). Although important, 
social mobilization and trainings were not financed in 
RI. For SIA, the three important recurrent cost compo-
nents were personnel (30.07  %), vaccines (29.93  %) and 
consumables (22.83 %). The larger cost share of vaccines 
in SIA is due to a larger target population of children up 
to 5 years of age whereas RI is only devoted to children 
under 1  year. It is to be noticed that per diems paid to 
the staff during SIA were higher than the total adjusted 
wages and allowances they received during 1 year.
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Effectiveness
SIA was more effective when referring to the number 
of vaccines used and the number of vaccinated children 
as it led to vaccinate five times more children than RI 
(Table  3). There were 742 previously unvaccinated chil-
dren (‘zero-dose’ children) among the 35,564 children 
vaccinated during SIA corresponding to 2 % of total tar-
get. More vaccines were wasted during RI (1387 wasted 
doses) than SIA (1106 wasted doses). Vaccine wastage 
rate (as defined by the number of doses used minus vac-
cinated targets over number of doses used) was lower for 
SIA (3 %) than RI (15 %). To the contrary, RI permitted 
Fig. 1 Diagram used to estimate the years of life lost
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to avoid more measles cases, measles deaths and DALYs 
than SIA (Table 4). The benefits of SIA was 5601 measles 
cases averted, 185 measles death averted and 6955 addi-
tional DALYs averted.
Average costs
Overall, the mean cost per vaccinated child was 590 FCFA 
(1 USD) but it was 1057 FCFA (2.20 USD) for RI and 431 
FCFA (0.90 USD) for SIA (Table 5). SIA had the best cost 
effectiveness ratios when referring to process outcomes 
whether considering the cost per MCV dose used or the 
cost per vaccinated child. In comparison with ‘no vaccina-
tion’, cost/DALY averted for RI was 769 FCFA (1.60 USD). 
The marginal cost was 2271 FCFA (4.73  USD) per sup-
plementary DALY averted for SIA. The two strategies put 
together had a cost/DALY averted of 1297 FCFA (3 USD).
Table 1 Base-case and alternative values of parameters used in the sensitivity analysis
Variations tested Base case values Alternatives values
Routine immunization Vaccines cost (MCV unit dose price) 120 FCFA/Dose 60–180 FCFA/Dose
Supervision cost: Increasing supervision frequency 4 supervisions per annum 6 supervisions per annum
Personnel cost : increasing total personnel cost 3,599,536 FCFA 7,199,072 FCFA
Inclusion of communication costs 0 371,000 FCFA
Exclusion of capital costs 14,748,858 FCFA 0
Vaccine efficacy 85 % 60–99 %
Measles CFR 6 % 0.00–31.25 %
RI coverage 89 % 50–98 %
Supplementary immunization activity Vaccines cost (MCV unit dose price) 120 FCFA/Dose 60–180 FCFA/Dose
Exclusion of capital costs 279,694 FCFA 0
Proportion of unvaccinated children (‘zero-dose’) 2 % 0–50 %
Vaccine efficacy 85 % 60–99 %
Measles CFR 6 % 0–31.25 %
SIA coverage 104 % 80–104 %
Table 2 Costs by component for measles RI and SIA in the health district of Natitingou in 2011
Cost components RI SIA Overall (RI + SIA)
Amount (FCFA) % Amount (FCFA) % Amount (FCFA) %
Reccurent costs
 Vaccines 1,118,400 11.35 4,728,000 29.93 5,846,400 22.79
 Consumables 391,161 3.97 3,606,188 22.83 3,997,350 15.59
 Personnel 3,599,536 36.54 4,750,000 30.07 8,349,536 32.55
 Transport 95,258 0.97 625,436 3.96 720,694 2.81
 Communication 0 0.00 371,000 2.35 371,000 1.45
 Trainings 0 0.00 454,000 2.87 454,000 1.77
 Supervision 220,579 2.24 830,550 5.26 1,051,129 4.10
 Maintenance 98,010 0.99 0 0.00 98,010 0.38
 Wastage management 58,501 0.59 137,500 0.87 196,001 0.76
 Surveillance 143,150 1.45 216,000 1.37 359,150 1.40
 Fuel for cold chain 396,900 4.03 7,541 0.05 404,441 1.58
 Electricity 36,464 0.37 693 0.00 37,156 0.14
Capital costs
 Buildings 1,188,000 12.06 22,572 0.14 1,210,572 4.72
 Cars and motorcycles 1,120,320 11.37 21,286 0.13 1,141,606 4.45
 Cold chain materials 1,385,658 14.06 25,793 0.16 1,411,451 5.50
 Total 9,851,938 100 15,796,560 100 25,648,498 100
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In the sensitivity analysis, the cost per DALY for RI 
varied from 0.37 to 7.98  USD (Fig.  2) and from 0.69 
to 15.40  USD for SIA (Fig.  3). In both cases, cost per 
DALY was more sensitive to changes in measles CFR. 
Reducing measles CFR from 31.25 to 0.00  % lead to an 
increase of the cost per DALY averted from 0.37 to 
7.98  USD for RI and from 0.69 to 15.40  USD for SIA. 
Exclusion of capital costs did not affect significantly the 
cost/DALY for the two strategies. However the analysis 
showed that cost-effectiveness ratios of the two strategies 
Table 3 Vaccine doses used, vaccinated children and  wasted doses of  measles RI and  SIA in  the health district 
of Natitingou in 2011
RI SIA Overall (RI + SIA)
Children receiving first dose Children receiving second  
dose
Total SIA
<1 year ≥1 year <1 year ≥1 year
Vaccine doses used 9320 360 400 2110 33,800 36,670 45,990
Vaccinated children 7933 349 393 2092 32,730 35,564 43,497
Wasted doses 1387 11 7 18 1070 1106 2493
Table 4 Measles cases averted, measles deaths averted 
and  DALYs averted for  RI and  SIA in  the health district 
of Natitingou in 2011
RI SIA Overall (RI + SIA)
Measles cases averted 6743 5601 12,344
Measles deaths averted 405 185 590
DALYs averted 12,815 6955 19,770
Table 5 Average costs for measles RI and SIA in the health district of Natitingou in 2011
RI SIA Overall (SIA + RI)
FCFA USD FCFA USD FCFA USD
Cost per dose used 1057 2.20 431 0.90 558 1
Cost per vaccinated child 1242 2.59 442 0.92 590 1
Cost per measles case averted 1461 3.04 2820 5.88 2078 4
Cost per measles death averted 24,351 50.73 85,422 177.96 43,508 91
Cost per DALY averted 769 1.60 2271 4.73 1297 3
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Fig. 2 Tornado diagram showing the range of cost/DALY averted for routine immunization (RI). The vertical line between $1 and $2 represents the 
base-case cost/DALY of RI compared to no intervention, along with the specific value calculated. The widths of the bars show the variation in cost/
DALY as each parameter is varied from lower bound to upper bound. $ USD
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varied significantly following vaccine coverage and vac-
cine efficacy. High vaccine coverage and high measles 
vaccine efficacy improve the cost-effectiveness of the 
two interventions. With a twofold increase of the base-
case personnel cost, the cost/DALY increased from 
1.6 to 2.2  USD. In the same manner, when trainings 
and communication costs were included in the base-
case analysis of RI, the cost/DALY only increased from 
1.5 to 1.75  USD. During SIA, when the proportion of 
‘zero-dose’ children vary from 0 to 50 %, the cost/DALY 
decrease from 5.39 to 1.21 USD.
Discussion
Regarding costs
Results from the present study are in line with previous 
studies on the fact that SIAs are costlier than RI [17, 18]. 
In this study, total cost of SIA for measles was 15,796,560 
FCFA (32,909.50 USD) versus 9,851,938 FCFA (20,524.87 
USD) for RI. Personnel and vaccines costs took the large 
part of the two strategies total cost (respectively 36.54 
and 11.35 % for RI; 30.07 and 29.93 % for SIA). ‘Person-
nel’ is usually cited among the highest cost components 
in immunization costs analysis [18–21]. In the context 
of Natitingou, close to that described in a Cameroo-
nian health district [21], medical staff was poorly paid. 
The highest wage for a health professional involved in 
immunization activities was 100,000 FCFA (208 USD) 
per month corresponding to 7 USD per day. During SIA, 
medical staff was paid 7000 FCFA (15 USD) per day. In 
addition, during SIA, community health workers were 
recruited and paid 5000 FCFA (10 USD) per day to sup-
port health professionals whereas they did not receive 
any incentives for their involvement in RI activities. This 
explains why personnel costs of SIA were higher than 
that for RI. In addition, savings were made in RI because 
social mobilization and staff trainings were not financed. 
A particular attention should be paid to the part took by 
fuel for cold chain functioning. With 4.03  % of RI total 
cost, it represents the third cost component behind per-
sonnel and vaccines. In fact, 83  % of refrigerators used 
for immunization activities were working with kerosene. 
Given, following WHO recommendations, vaccines 
needs to be permanently stored at health facility level at 
a temperature between +2 and +8  °C, kerosene supply 
was a requisite and incompressible expenditure. The use 
of cold chain material working with solar energy in set-
tings without electricity as alternative should be explored 
by policy makers in Benin. Savings could be possible 
with this material, as it requires no fuel for functioning 
and there is no need of regular spare parts replacement 
(burners, wicks, glasses) unlike kerosene-functioning 
refrigerators.
Regarding effectiveness
RI permitted to vaccinate 89 % of the target population, 
under the 95  % recommended by the national immuni-
zation program. In contrast, SIA reached 104  % of the 
target in short time of period (7  days). It permitted to 
vaccinate 35,564 under-five children and the benefit was 
5601 supplementary measles cases averted converted to 
6955 additional DALYs averted. SIA permitted to save 
185 children who should have probably died from mea-
sles despite RI. This strength of SIA to reach usually 
unreachable children through RI make it an intervention 
that contributes to equity in health and a preferable plat-
form to deliver second dose of MCV in settings where RI 
is not effective enough [16, 22, 23]. Fewer vaccines were 
lost during SIA compared to RI (3 % of vaccine wastage 
$0 $2 $4 $6 $8 $10 $12 $14 $16 $18
Vaccines cost (MCV unit dose price)
Exclusion of capital costs




Fig. 3 Tornado diagram showing the range of cost/DALY averted for supplementary immunization activity (SIA). The vertical line between $4 and $6 
represents the base-case cost/DALY of SIA compared to no intervention, along with the specific value calculated. The widths of the bars show the 
variation in cost/DALY as each parameter is varied from lower bound to upper bound. $ USD
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rate versus 15 %). It could be the direct consequence of 
non-financing social mobilization activities in RI. Yet, 
social mobilization contributes to encourage and moti-
vate the public to fully participate in immunization activ-
ities. Thus, it helps to gather a lot of targets at vaccination 
location and then lowers vaccine wastage by applying 
open vial policy for lyophilized vaccines (MCV should be 
used within 6 h after the vial being opened).
Regarding efficiency
In accordance with estimations in Niger (190 FCFA for 
SIA and 573 FCFA for RI) [17] and Uganda (0.58 USD for 
SIA and 1 USD for RI) [24], the cost per vaccinated child 
in this study was lower for SIA than RI (431 FCFA versus 
1051 FCFA). SIA cost per vaccinated child was similar to 
findings for poliomyelitis mass campaigns conducted in 
West Africa [18, 20, 25]. SIA had better productive effi-
ciency indicators because more children were reached 
and fewer vaccines were wasted. To improve RI produc-
tive efficiency, more political and community implica-
tion should be conjugated to higher health professionals’ 
motivation, media and local leaders’ mobilization. Unfor-
tunately, as shown by cost structures’ analysis, financ-
ing communication activities and staff trainings was 
neglected by the health district.
Whatever is the strategy used, measles immunization 
is known to be a cost-effective intervention [23, 24]. In 
our study, in comparison with no intervention, cost per 
DALY averted was 2271 FCFA (4.73 USD) for SIA; 769 
FCFA (1.60 USD) for RI and 1297 FCFA (3 USD) for 
both strategies combined. These cost-effectiveness ratios 
are quite under those of interventions known to be the 
most efficient interventions in Afro-E, a WHO defined 
region comprising countries in sub-Sahara Africa with 
high child mortality [26]. Analysis showed that cost per 
DALY averted never exceeded 16 USD whatever the 
possible extreme variations of chosen parameters were. 
The cost per DALY was higher, but still under 16 USD, 
when measles CFR was very low (0.00  %). But it seems 
to be an extreme scenario as it is far to be the case in 
the health district of Natitingou and most of health dis-
tricts of Benin, where malnutrition, vitamin A deficiency, 
poor cases management and intercurrent infections like 
malaria and HIV contribute to high measles fatality rate. 
A twofold increase of personnel costs did not impact 
negatively the cost/DALY for RI neither was inclusion of 
trainings and communication costs in the base-case anal-
ysis. Therefore, there is no need to make savings on these 
cost components. In contrary, allocating funds to this 
cost components would increase the attention of health 
professionals to RI activities and contribute indirectly to 
a greater efficiency. SIA was more cost-effective when 
the proportion of previously unvaccinated was higher. 
In other words, more RI failed to vaccinate targeted chil-
dren, more SIA became a cost-effective intervention.
Implications for decision‑making
Since non-financing communication activities is preju-
dicial to RI effectiveness, the health district managers 
should plan and finance annually social mobilization 
activities for RI. District administration needs also to 
organize short-term trainings for health profession-
als as it will strengthen their capacity in conducting 
vaccination activities and it can increase their motiva-
tion. There is a need for immunization policy makers 
in Benin to think about adopting low-cost cold chain 
materials in terms of energy consumption. As dis-
cussed above, there is possibility to make savings with 
solar system materials. Importantly, vaccine efficacy 
should be maintained at its highest level to improve the 
efficiency of both RI and SIA. In other words, vaccine 
should be properly stored and transported respecting 
the recommended temperature at all steps of the sup-
ply chain. Measles vaccine is very sensitive to heat and 
rapidly lost its efficacy when exposed to temperature 
over +8 °C for a long time. Usually, breaks in cold chain 
occurs at health facility level or at vaccination delivery 
point where health professionals fail to keep the vac-
cine in the right temperature because of poor cold chain 
materials maintenance.
Health districts in Benin are organized in the same 
way. Staffing and resources for immunization activities 
are allocated in the same manner. Moreover, vaccination 
strategies are the same and measles epidemiologic pro-
file is not different from one health district to another. 
Accordingly, results from this study and the recom-
mendations derived from it could be transposed to any 
other health district of the country. In the same way, 
the results could be useful to immunization policy mak-
ers in other sub-Saharan African countries with similar 
measles disease burden and with the same health system 
organization.
Limitations
The use of primary data empirically obtained from the 
field is a strength of this study. Moreover, this study 
estimated the costs of delivering one single antigen 
among those administrated through RI, an unusual case 
in the literature. However, the study has some limita-
tions. Transport and maintenance costs for RI may have 
been inaccurately estimated because distances covered 
by motorcycles were based on health professionals’ 
statements. Measles mortality may have been inaccu-
rately estimated because we did not used measles case 
fatality rate in Benin due to lack of accurate data. Mea-
sles case fatality rates used came from published data 
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for countries with a similar epidemiological profile to 
Benin regarding measles. Vaccine coverage should be 
interpreted carefully because denominators used (tar-
geted children) came from an old national census. There 
are shortcomings of relying on old GBD data although 
GBD-2010 data were available [27]. The comprehensive 
sensitivity analysis conducted with large ranges of val-
ues helped to address these uncertainties (Additional 
file 1).
Conclusion
Key findings from this operational research, the first to 
be conducted on the costs and effectiveness of measles 
vaccination strategies in Benin, could be summarized as 
followed:
  • First, SIA for measles cost more than RI for measles. 
However, costs structure of the two strategies was 
disproportionate.
  • Second, SIA and RI for measles are cost-effective 
interventions to improve health in Benin compared 
to no vaccination. The proportion of ‘zero-dose’ chil-
dren affects significantly SIA cost-effectiveness. A 
twofold increase of personnel costs or inclusion of 
trainings and communication costs in the base-case 
analysis do not impact negatively the cost/DALY for 
RI.
Benin have set measles elimination goal for the year 
2020. It is possible to meet this goal if sufficient funds 
are mobilized and efficiency is taken into account. This 
work address the question of the costs, the effectiveness 
and the efficiency of delivering two dose of measles vac-
cination combining RI and SIA at district level in Benin. 
Future studies should be focused on measles immuniza-
tion activities financing to identify how to ensure sustain-
able funding.
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